Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial - Reck, M; Schenker, M; Lee, KH (Eur J Cancer, 2019)
et al.